Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.

OBJECTIVES To determine the protective efficacy of highly active antiretroviral therapy (HAART) against AIDS dementia complex (ADC) relative to other initial AIDS-defining illnesses (ADIs), Australian AIDS notification data over recent years were examined. METHODS All initial ADIs in Australia over the period 1992-1997 were included. Three initial ADI groups were established: ADC; other predominantly central nervous system (CNS) ADIs (toxoplasmosis and cryptococcosis); and non-CNS ADIs. For each ADI grouping, the proportion of total ADls, and median CD4 cell count in the pre-HAART era (1992-1995) were compared with the HAART era (1996 and 1997). RESULTS Initial ADls peaked in Australia in 1994 (n = 1049), with a gradual decline to 1996 (n = 722), and a marked decline in 1997 (n = 367). ADC constituted 4.4% of initial ADIs over the period 1992-1995, but increased after the introduction of HAART to 6.0% in 1996 and 6.5% in 1997 (P = 0.02). In contrast, the proportion of other CNS ADIs (1992-1995, 8.1%; 1996, 6.0%; 1997, 8.2%; P = 0.41) was stable over the period 1992-1997. The median CD4 cell count at ADC diagnosis increased from 70/mm3 in 1992-1995 to 120/mm3 in 1996 and 170/mm3 in 1997 (P = 0.04). Although the median CD4 cell count also increased significantly over this period for both other CNS ADIs (40-60/mm3; P = 0.02), and non-CNS ADIs (60-70/mm3; P = 0.02), the increase was small. CONCLUSION A proportional increase in ADC compared with other ADIs and a marked increase in the median CD4 cell count at ADC diagnosis have occurred since the introduction of HAART in Australia. These changes suggest that HAART has a lesser impact on ADC than on other ADIs, with the poor CNS penetration of many antiretroviral agents a possible explanation.

[1]  J. Cuzick,et al.  A Wilcoxon-type test for trend. , 1985, Statistics in medicine.

[2]  D. Gertig,et al.  The acquired immunodeficiency syndrome in Australia: incidence 1982–1991 , 1993, The Medical journal of Australia.

[3]  J. Phair,et al.  Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. , 1993, The New England journal of medicine.

[4]  M. Tagliati,et al.  Neurologic Manifestations of HIV Infection , 1994, Annals of Internal Medicine.

[5]  B. Brew,et al.  The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid. , 1996, Journal of neurovirology.

[6]  F. Dromer,et al.  Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[8]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[9]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[10]  F. Wit,et al.  Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial , 1997 .

[11]  S. Mallal,et al.  Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[12]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[13]  B. Brew,et al.  Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. , 1997, The Journal of infectious diseases.

[14]  D. Richman,et al.  In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues , 1997, Journal of virology.

[15]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[16]  P. Massip,et al.  Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres , 1997, AIDS.

[17]  H. Brodt,et al.  Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy , 1997, AIDS.

[18]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[19]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[20]  B. Brew.  Neurological efficacy of stavudine, zidovudine, and lamivudine , 1998, The Lancet.

[21]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[22]  I. Keet,et al.  Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine , 1998, The Lancet.